Rehmann Capital Advisory Group’s Coherus Oncology CHRS Stock Holding History

Rehmann Capital Advisory Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$850	Buy	+42	New	+$839	﹤0.01%	1585

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Rehmann Capital Advisory Group's CHRS Position: Q3 2019 in Review

Rehmann Capital Advisory Group opened a new position in Coherus Oncology (CHRS) in Q3 2019: 42 shares worth $850. The stake represents ﹤0.01% of the portfolio and ranks #1585 among its holdings.

167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

Rehmann Capital Advisory Group held 42 shares of Coherus Oncology worth $850 as of Q3 2019.
Coherus Oncology was a new Rehmann Capital Advisory Group position in Q3 2019.
Coherus Oncology made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1585 holding.
167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.